|
KMID : 0928520090190020201
|
|
Korean Journal of Lipidology
2009 Volume.19 No. 2 p.201 ~ p.208
|
|
|
Simvastatin Decreases Soluble Tissue Factor Antigen Levelsin Hypercholesterolemic Patients
|
|
Park Kyung-Woo
Seo Jae-Bin
Kim Sang-hyun
Kim Yong-seok
Yang Han-mo
Kang Hyun-Jae
Oh Byung-Hee
Park Young-Bae
Kim Hyo-soo
|
|
|
Abstract
|
|
|
Background: Statin therapy has been shown to have various mechanisms of benefit beyond lipid lowering such as reduction of inflammation and thrombogenicity. The purpose of the study was to examine whether the attenuation of inflammation by statin therapy is related to the decrease in soluble tissue factor antigen (sTF:Ag) levels in hypercholesterolemic patients.
Methods and results: Fifteen patients with LDL-C >130 mg/dL after 4 weeks of diet therapy were given simvastatin 20 mg daily for 4 weeks. Lipid profiles, plasma levels of sTF:Ag, IL-1β, IL-6, and TNF-α were measured before and after simvastatin treatment. Compared with pretreatment values, simvastatin significantly lowered total cholesterol (by 31%) and LDL-C level (by 42%) while effects on triglycerides and HDL-C were insignificant. The levels of proinflammatory cytokines and sTF:Ag were all significantly reduced by simvastatin treatment (by 51%, 57%, 38%, and 43% for sTF:Ag, TNF-α, IL-1β, and IL-6 respectively, P<0.05). In contrast to the lack of correlation between the decrease in sTF:Ag levels and the change in LDL-C levels, there were significant correlations between changes in proinflammatory cytokine levels and the decrease in sTF:Ag.
Conclusion: In hypercholesterolemic patients, simvastatin therapy for 4 weeks significantly reduces markers of inflammation, which is related to the decrease in soluble tissue factor antigen. Our data confirm previous reports on the non-lipid role of statins in reducing inflammation and possibly thrombogenicity.
|
|
|
KEYWORD
|
|
|
Statin, Inflammation, Tissue factor, Hypercholesterolemia
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|